

CLAIMS:

1. An immunogenic composition comprising a GBS saccharide antigen and at least two GBS polypeptide antigens, wherein said GBS saccharide antigen comprises a saccharide selected from GBS serotype Ia, Ib, and III, and wherein said GBS polypeptide antigens comprise a combination of at least two polypeptide or fragments thereof selected from the antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 147, GBS 173, GBS 276, GBS 305, GBS 313, GBS 322, GBS 328, GBS 330, GBS 338, GBS 358, GBS 361, GBS 404, GBS 656, GBS 690, and GBS 691.
2. The immunogenic composition of claim 1, wherein said GBS polypeptide antigens further comprise a GBS polypeptide or a fragment thereof of serogroup II.
3. The immunogenic composition of claim 1, wherein said GBS polypeptide antigen combination comprises GBS 80 or a fragment thereof.
4. The immunogenic composition of claim 3, wherein said GBS polypeptide antigens comprise a combination of two GBS antigens or fragments thereof selected from the group consisting of (1) GBS 80 and GBS 91, (2) GBS 80 and GBS 104, (3) GBS 80 and GBS 147, (4) GBS 80 and GBS 173, (5) GBS 80 and GBS 276, (6) GBS 80 and GBS 305, (7) GBS 80 and GBS 313, (8) GBS 80 and GBS 322, (9) GBS 80 and GBS 328, (10) GBS 80 and GBS 330, (11) GBS 80 and GBS 338, (12) GBS 80 and GBS 358, (13) GBS 80 and GBS 361, (14) GBS 80 and GBS 404, (15) GBS 80 and GBS 656, (16) GBS 80 and GBS 690, and (17) GBS 80 and GBS 691.
5. The immunogenic composition of claim 4, wherein said combination is selected from the group consisting of (1) GBS 80 and GBS 338; (2) GBS 80 and GBS 361, (3) GBS 80 and GBS 305, (4) GBS 80 and GBS 328, (5) GBS 80 and GBS 690, (6) GBS 80 and GBS 691 and (7) GBS 80 and GBS 147.

6. The immunogenic composition of claim 4, wherein said combination comprises GBS 80 and GBS 691.
7. The immunogenic composition of claim 1, wherein said composition comprises a combination of at least three GBS polypeptide antigens.
8. The immunogenic composition of claim 7, wherein said combination comprises GBS 80 and GBS 691.
9. The immunogenic composition of claim 7, wherein said combination comprises GBS 80.
10. The immunogenic composition of claim 1, wherein at least one GBS polypeptide antigen is covalently linked to the GBS saccharide antigen.
11. The immunogenic composition of claim 1, wherein said GBS saccharide antigen is covalently linked to a carrier protein.
12. The immunogenic composition of claim 11, wherein said carrier protein is selected from the group consisting of tetanus toxoid, diphtheria toxoid, *N. meningitides* outer membrane protein, heat shock protein, pertusis protein, protein D from *H. influenzae*, and toxin A or B from *C. difficile*.
13. The immunogenic composition of claim 12, wherein said carrier protein is selected from the group consisting of tetanus toxoid and diphtheria toxoid.
14. The immunogenic composition of claim 13, wherein said carrier protein is a diphtheria toxoid.
15. The immunogenic composition of claim 14, wherein said diphtheria toxoid is CRM197.

16. A method for the therapeutic or prophylactic treatment of GBS infection in an animal susceptible to GBS infection comprising administering to said animal a therapeutic or prophylactic amount of the immunogenic composition of claim 1.

17. A method for the manufacture of a medicament for raising an immune response against GBS comprising combining a GBS saccharide antigen and at least two GBS polypeptide antigens, wherein said GBS saccharide antigen comprises a saccharide selected from GBS serotype Ia, Ib, and III, and wherein said GBS polypeptide antigens comprise a combination of at least two polypeptide or fragments thereof selected from the antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 147, GBS 173, GBS 276, GBS 305, GBS 313, GBS 322, GBS 328, GBS 330, GBS 338, GBS 358, GBS 361, GBS 404, GBS 656, GBS 690, and GBS 691.